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Abstract
Objective:
Safety and efficacy of levetiracetam in a man with
hemifacial spasm (HFS).
Methods and Results:
The present work reports the case of a 54-year-old
man with a 5-year history of left-sided HFS who,
after treatment with levetiracetam (dosage, 500 mg
bid), showed a marked improvement in condition.
After 7 months of therapy with levetiracetam, the
patient remains symptom free with no adverse
drug reactions.
Conclusions:
Levetiracetam proved its effectiveness and safety
in the treatment of a case of HFS.
Nevertheless, there is a need for further controlled
studies with larger samples.
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Hemifacial spasm (HFS) consists of unilat-eral involuntary and paroxysmal con-
tractions of facial muscles innervated by the
seventh cranial nerve. Its incidence rate in
the United States is 0.5 case per 100,000
persons for ages 60 to 79 years.1
Primary HFS is generally caused by
vascular compression of the nerve’s root
exit zone from the brainstem. Often, vascu-
lar loops can be demonstrated by imaging
studies; in addition, patients who are not
affected by organic disease in which the
results of imaging studies are normal are
diagnosed as having primary HFS. Secondary
HFS is associated with space-occupying
lesions in the brainstem or posterior cranial
fossa, traumatic events, demyelinating disor-
ders, and Bell palsy. Primary HFS initially
involves periocular muscles and then
spreads to the neighboring facial muscles
(orbicularis oris and platysma); secondary
HFS simultaneously involves the upper and
the lower facial muscles. This different
clinical presentation is related to causative
differences between the 2 forms and to the
organization of facial nerve motor fibers.
Because facial nerve motor fibers are topo-
graphically organized at the root entry zone,
primary HFS gradually involves facial
muscles, whereas damage of the temporal
portion of facial nerve, where fibers become
more diffusely arranged, involves all facial
muscles at the same time.2 Although HFS is a
benign condition, it can cause significant
cosmetic and functional disability, and
patients rarely recover spontaneously.
Levetiracetam is indicated for the treat-
ment of partial seizures with or without
secondary generalization in epilepsy, but
some reports indicate its effectiveness in
the treatment of tardive dyskinesia.3,4 More-
over, Deleu5 described 2 cases of idiopathic
HFS in which levetiracetam (dosage, 500 mg
3 a day) proved efficacious; in this report,
both patients had been previously treated
with botulinum toxin type A with a short
period of relief and disabling adverse effects.
We report the case of a patient with HFS
who responded favorably to levetiracetam.
MATERIALS AND METHODS
In June 2006, we examined a man (age,
54 years) with a 5-year history of left-sided
HFS. The symptoms of HFS developed grad-
ually. Initially, they involved upper facial
muscles. After 1 year, they spread to lower
facial muscles; there was no association with
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Bell palsy. The patient presented involuntary
tonic-clonic contractions of the eye and
mouth orbicular muscles and the platysma;
involuntary eye closure interfered with
vision. He was hypertensive in treatment
with nifedipine (dose, 30 mg/die). Blood test
results were normal. Magnetic resonance
angiography of the cerebellopontine angle
had been also performed and revealed no
pathological elements. The patient had been
previously treated with clonazepam (dosage,
12 mg bid) for 2 months with no results.
RESULTS
The patient was treated with levetir-
acetam (dosage, 250 mg bid) for 2 weeks
with no benefit. We decided to change the
trial dosage to 500 mg bid, and we observed
a gradual regression of symptoms during a 3-
week period. After 5 weeks of therapy with
levetiracetam, involuntary movements disap-
peared at all. Three months later, the patient
spontaneously reduced the dosing of levetir-
acetam to 250 mg bid for 2 weeks with the
reappearance of the disorder; rechallenge
with levetiracetam resulted in total regres-
sion of visible spasm.
After 7 months of therapy, the patient
remains symptom free with no adverse drug
reactions.
DISCUSSION
The 2 most commonly used treatments
for HFS are botulinum toxin injections and
surgical microvascular decompression. Botu-
linum toxin injections around the eye and
cheek result in symptomatic relief and have
no serious adverse effects, but they need to
be repeated every few months indefinitely
with high cost.6 Surgical microvascular
decompression also offers relief and, unlike
botulinum toxin treatment, it provides a
permanent solution with a small chance of
serious complication.1 There are also some
reports about the efficacy of gabapentin or
pregabalin in the treatment of HFS.7Y9
The temporal relationship between
drug exposure and clinical effects has shown
the usefulness of levetiracetam in the manage-
ment of our case of HFS. Levetiracetam can be
a suitable therapeutic option for patients who
are intolerant or resistant to botulinum infil-
trations10 and is an interesting alternative to
repeated botulinum injections. Additional
studies to confirm the efficacy of levetirace-
tam in the treatment of HFS are necessary.
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